NEJM.org
LightNews LightNews
banner
nejm.org
NEJM.org
@nejm.org
22K followers 260 following 1.7K posts
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org.

Follow @ai.nejm.org for medical AI content.
Posts Replies Media Videos
Pinned
nejm.org
NEJM.org @nejm.org · 4d
A new Double Take video reviews evidence-based recommendations on measles prevention and management and explores commonly asked questions about the measles virus and infection. Watch on YouTube: youtu.be/PI6M680p9i0
Measles | NEJM
YouTube video by NEJM Group
youtu.be
nejm.org
A 50-year-old woman was admitted to the hospital because of fever and abdominal pain after visiting rural Brazil. Shock and disseminated intravascular coagulation developed. What is the most likely diagnosis in this case?

 🗳️ Cast your vote before January 8: nej.md/3Yfizns
December 26, 2025 at 2:30 PM
nejm.org
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg
The New England Journal of Medicine ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
December 26, 2025 at 2:23 PM
nejm.org
A new interactive feature describes a 34yo man who presented to the hospital w/ exercise intolerance, night sweats & bradycardia. 2 wks before the current presentation, he had seen his physician after a vacation along the Massachusetts coast. Test your diagnostic & therapeutic skills: nej.md/4qkJFWl
Interactive Medical Case Tick Tock An illustration of the patient lying in a hospital bed
December 25, 2025 at 8:01 PM
nejm.org
An 80-year-old man presented with a 4-day history of a rash on his abdomen. What is the most likely diagnosis? Submit your answer: nej.md/4jmqkBS

#MedSky
December 24, 2025 at 11:21 PM
nejm.org
A 38-year-old woman presented with a 12-month history of annular plaques on the forehead, cheeks, and neck. Skin biopsy revealed noncaseating epithelioid granulomas with sparse lymphocytic infiltration in the superficial dermis. Read the full case details: nej.md/3L26Llk

#MedSky #DermSky #PulmSky
Images in Clinical Medicine Cutaneous Sarcoidosis with Annular Plaques Photos of the brownish-red annular plaques with a thinly raised border and central hypopigmentation with slight atrophy in areas on the forehead (Panel A), as well as on the cheeks and neck (Panel B).
December 24, 2025 at 11:00 PM
nejm.org
Case Record of the Massachusetts General Hospital: A 55-year-old woman with myasthenia gravis was admitted to the hospital with recurrent gastrointestinal bleeding. Upper and lower endoscopy did not reveal a source of bleeding. A diagnosis was made. Read the full case details: nej.md/48Jytwv
Case Records of the Massachusetts General Hospital A 55-Year-Old Woman with Dyspnea, Fatigue, and Gastrointestinal Bleeding CT angiography
December 24, 2025 at 10:10 PM
nejm.org
SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized in a new Quick Take video. nej.md/4s7lv3m
Visual representation of the SURPASS-CVOT trial, which compared cardiovascular outcomes between tirzepatide, a dual GLP-1 and GIP agonist, with dulaglutide, a GLP-1 receptor agonist.
December 24, 2025 at 2:02 PM
nejm.org
Visit NEJM.org Wednesday at 5 PM ET for a brand-new Case Challenge and test your diagnostic skills. 

#MedSky
Coming Soon! Case Challenge An axial image from non–contrast-enhanced CT of a patient's abdomen and pelvis
December 23, 2025 at 8:03 PM
nejm.org
A 75-year-old man with hypertension was brought to the emergency department after a motor vehicle collision. A video recording from the dashboard camera in his car showed a loss of ability to react to events on his left side. Read the full case details: nej.md/48GkW8U  

#MedSky #NeuroSky
December 23, 2025 at 2:02 PM
nejm.org
NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD, discusses a recent study that examined a less-intensive, conservative approach to dialysis in patients with severe acute kidney injury. Read the full summary and see what else is in this week's edition at clinician.nejm.org.
December 22, 2025 at 4:09 PM
nejm.org
A new Double Take video reviews evidence-based recommendations on measles prevention and management and explores commonly asked questions about the measles virus and infection. Watch on YouTube: youtu.be/PI6M680p9i0
Measles | NEJM
YouTube video by NEJM Group
youtu.be
December 22, 2025 at 2:02 PM
nejm.org
HPV vaccination could prevent most cervical cancers, but only 27% of eligible adolescent girls worldwide have received the vaccine. Data suggest that a single dose may be protective. Research findings from the ESCUDDO trial are summarized in a new Quick Take video. nej.md/3MFcHBr

#MedSky #IDSky
A visual representation of the ESCUDDO trial, which examined whether a single dose of HPV vaccination could help to protect adolescent girls against most cervical cancers.
December 21, 2025 at 2:00 PM
nejm.org
A 6-month-old baby boy was referred to a pediatric neurology clinic in Brazil for evaluation of developmental delay. At the beginning of the second trimester, the baby’s mother had had a rash. At birth, the baby had microcephaly. 1/2

#MedSky #PedSky #NeuroSky
December 20, 2025 at 2:02 PM
nejm.org
A 72-year-old woman presented with a 3.5-month history of an enlarging, painless lump on her cheek. Examination showed a dome-shaped, reddish nodule on the left cheek, with a shiny surface and central hemorrhagic crust. Read the full case details: nej.md/3MDwXU5

#MedSky #DermSky #Oncology
Images in Clinical Medicine Merkel-Cell Carcinoma Panel A: Photo of the dome-shaped, reddish nodule surrounded by erythema on the left cheek. Panel B: A punch biopsy of the lesion revealing dermal infiltration by small, round, blue cells arranged in nests, as well as scant cytoplasm and hyperchromatic nuclei; mitoses were frequently observed.
December 19, 2025 at 8:31 PM
nejm.org
Take a look back at the numbers that went into a year of publishing at the world’s leading medical journal.

To discover the 15 articles NEJM editors selected as among the most impactful in advancing clinical practice and patient care this year, download the Notable Articles of 2025: nej.md/3YD0EXU
December 19, 2025 at 4:19 PM
Reposted by NEJM.org
paulsaxmd.bsky.social
Inspired by a @nejm.org piece by Drs Brian Garibaldi and Steven Russell, I add my two cents on the physical examination.

Because limitations notwithstanding, it still matters. blogs.nejm.org/hiv-id-obser...
What Use Is the Physical Examination in Current Medical Practice?
Share Tweet Pin Mail SMS A very interesting, quite scholarly perspective appeared in the NEJM last month called, “Strategies to Reinvigorate the Bedside Clinical ...
blogs.nejm.org
December 18, 2025 at 10:36 PM
nejm.org
In a Review Article on measles, Lien Anh Ha Do, MD, PhD, and Kim Mulholland, MB, BS, MD, review the epidemiology, clinical presentation, and associated illnesses as well as treatment and prevention strategies. Read the full review: nej.md/4lmC1Ir

#MedSky #PedSky #IDSky
December 19, 2025 at 2:03 PM
nejm.org
After cystectomy for muscle-invasive bladder cancer, many patients are at risk for recurrence. Research findings from the IMvigor011 phase 3 trial are summarized in a new Quick Take video. nej.md/4p0xrB4

#MedSky #Oncology
A visual representation of the IMvigor011 phase 3 trial, which evaluated atezolizumab as compared with placebo as adjuvant therapy in patients at risk for recurrence after cystectomy who tested ctDNA-positive.
December 18, 2025 at 8:00 PM
nejm.org
New in the December 18/25, issue of NEJM:

ctDNA-Guided Atezolizumab in Bladder Cancer (IMvigor011 phase 3 trial) nej.md/3WIRtEg

Cardiovascular Outcomes with Tirzepatide (SURPASS-CVOT trial) nej.md/4qd5rLx

#MedSky
Images and descriptions of what's new on NEJM.org this week
December 18, 2025 at 2:01 PM
nejm.org
Tuberculous meningitis is often fatal, and current therapies need to be improved. In the HARVEST phase 3 trial, high-dose rifampin plus standard treatment was assessed. Full trial results: nej.md/49iiDsQ

#MedSky #NeuroSky #IDSky
Kaplan–Meier curves for 6-month survival according to treatment group and HIV status.
December 17, 2025 at 11:00 PM
nejm.org
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: nej.md/4qd5rLx

#MedSky #EndoSky #CardioSky
A figure showing the cumulative incidence of a composite of death from cardiovascular causes, myocardial infarction, or stroke (the primary efficacy end point).
December 17, 2025 at 10:10 PM
nejm.org
A 26-year-old woman presented with left elbow pain after falling on an outstretched hand while ice-skating. Radiographs showed a fracture of the proximal third of the ulnar shaft and a posterior dislocation of the radial head. Full case details: nej.md/3KJKs3K

#MedSky #Orthopedics #Radiology
Images in Clinical Medicine Monteggia Fracture Radiographs of the left elbow
December 17, 2025 at 8:04 PM
nejm.org
NEJM Evidence, in partnership with CIDRAP, announces the launch of Public Health Alerts, a new section featuring descriptive reports on topics of #PublicHealth importance. Learn more: eviden.cc/3KWhu0P

#MedSky
“The Public Health Alerts section, through the new partnership between CIDRAP and NEJM Evidence, seeks to advance our core mission: improving human health by putting actionable data in the public domain to inform clinicians, scientists, public health practitioners, policy makers, and the public.” Editorial “Public Health Alerts — A New Section in NEJM Evidence, in Partnership with CIDRAP” by C.A. Sacks et al.
December 17, 2025 at 5:32 PM
Reposted by NEJM.org
ai.nejm.org
In the latest episode of the AI Grand Rounds podcast, Dr. Zak Kohane, editor-in-chief of NEJM AI, explains why this year’s advances in #AI were personal, why it’s spreading fast, and why its most profound theme is values. Full episode: nejm.ai/ep37

#MedSky #MLSky
AI Grand Rounds Episode 37 What Values Are in AI? A Conversation with Dr. Zak Kohane A photo of Dr. Kohane
December 17, 2025 at 3:30 PM
nejm.org
In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy. Full RC48-C016 phase 3 trial results and Research Summary: nej.md/3W76VtS
The New England Journal of Medicine Disitamab Vedotin–Toripalimab in HER2-Expressing Urothelial Cancer A Research Summary based on Sheng X et al. | 10.1056/NEJMoa2511648 | Published on October 19, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
December 17, 2025 at 2:04 PM